The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with irritable bowel syndrome with constipation (IBS-C), as the former ...

Ironwood IRWD announced that the FDA has approved Linzess (linaclotide) as a once-daily treatment for functional constipation in pediatric patients aged 6-17 years. This approval for the new ...

Ironwood Pharmaceuticals, Inc. IRWD announced that it has initiated a phase IIIb study to expand the label of its drug, Linzess (linaclotide), for adding new bothersome symptoms associated with ...

Ironwood and Allergan have long pinned hopes for IBS drug Linzess on getting patients to switch from over-the-counter remedies to treat constipation. New pain and bloating data for Linzess could help ...